Based on the latest data from August 2025, Johnson & Johnson (JNJ) is trading at $177.17, positioning the stock in the overvalued zone between the 18.1x PE multiple ($170.88) and 22.6x PE multiple ($213.24). This indicates that JNJ is currently trading at approximately 20-21 times earnings, suggesting the stock is priced above its fair value range and may warrant caution from investors seeking entry points. Analyzing the historical trend, JNJ's valuation has experienced significant fluctuations over the past five years. The stock traded in undervalued to fair value territory throughout most of 2020-2022, with prices generally below the 18.1x PE boundary. A notable shift occurred in late 2023 when the PE boundaries expanded dramatically, reflecting changes in the company's earnings profile. From October 2023 through mid-2024, the stock actually traded in undervalued territory despite higher absolute prices due to this boundary expansion. However, since late 2024, JNJ has migrated back into overvalued territory, with the current price of $177.17 representing a premium valuation. The PE river chart shows periods of both expansion and contraction, with the most recent trend suggesting investors are paying higher multiples for JNJ's earnings compared to historical norms, indicating reduced margin of safety for new investments at current levels.